Impact of the 13-Valent Pneumococcal Conjugate Vaccine on the Incidence of All-cause Pneumonia in Adults Aged ≥60 Years: A Population-based, Retrospective Cohort Study
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
In this population-based study evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine (2012-2016) to prevent all-cause pneumonia in adults ≥60 years of age, we found significant, 0.63% absolute risk and 11.9% relative risk reductions on the 3-year (2014-2016) cumulative incidences of all-cause pneumonia after vaccination.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 2117-2119 |
| Number of pages | 3 |
| Journal | Clinical Infectious Diseases |
| Volume | 68 |
| Issue number | 12 |
| Publication status | Published - 30 May 2019 |
| Peer-reviewed | Yes |
External IDs
| ORCID | /0000-0001-6022-6827/work/127321423 |
|---|---|
| Scopus | 85067288466 |
Keywords
Sustainable Development Goals
Keywords
- Aged, Aged, 80 and over, Female, Humans, Incidence, Male, Middle Aged, Pneumococcal Vaccines/administration & dosage, Pneumonia, Pneumococcal/epidemiology, Population Surveillance, Retrospective Studies, Vaccination